Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system - Scorecard - MDSpire
Advertisement
Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system
Clinical Scorecard: Severe renal and pancreatic adverse effects linked to ipilimumab and nivolumab combination therapy in patients with non-small cell lung cancer: Insights from a pharmacovigilance study using the FDA adverse event reporting system
At a Glance
Category
Detail
Condition
Non-small cell lung cancer (NSCLC)
Key Mechanisms
CTLA-4-dependent disruption of B-cell tolerance and PD-1-mediated release of T-cell cytotoxicity
Target Population
Patients with advanced non-small cell lung cancer
Care Setting
Oncology clinics and hospitals
Key Highlights
Significant signals for glomerular-predominant renal injury and pancreatic toxicity associated with Ipi+Nivo therapy.
Median time-to-onset for renal events was 73 days and for pancreatic events was 84 days in the combination therapy group.
Co-reported renal and pancreatic events were infrequent in combination therapy reports.
Guideline-Based Recommendations
Diagnosis
Monitor for renal and pancreatic adverse events in patients receiving Ipi+Nivo therapy.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.
